Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSR-022 in Advanced Solid Tumors (AMBER)
NCT02817633Phase 1Active, not recruiting
- Start
- Jul 2016
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of cobolimab in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 2 more. Started Jul 2016; status: active, not recruiting.
02
Drugs
cobolimab
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02817633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02817633.